Entereg’s REMS To Assess Off-Label Use In Quarterly Reports To FDA
Executive Summary
Adolor will monitor off-label use of Entereg (alvimopan) under the Risk Evaluation and Mitigation Strategy for the postoperative constipation therapy, but the firm is silent on how it will handle situations of non-compliance with the drug's required controlled distribution system
You may also be interested in...
Fluoroquinolone REMS Will Survey Patients, Doctors on Understanding of Risk
FDA's risk evaluation and mitigation strategy for fluoroquinolone antibiotics requires manufacturers to survey patients and prescribers to make sure they understand the risks of tendon injury associated with the products
Fluoroquinolone REMS Will Survey Patients, Doctors on Understanding of Risk
FDA's risk evaluation and mitigation strategy for fluoroquinolone antibiotics requires manufacturers to survey patients and prescribers to make sure they understand the risks of tendon injury associated with the products
TNF Blockers’ Link To Cancer In Children Is Under FDA Investigation
FDA expects an investigation into the link between tumor necrosis factor blockers and lymphoma and other cancers in children will be completed in about six months